Alzheimer's vaccine clears plaque but has little effect on learning and memory impairment

A promising vaccine being tested for Alzheimer's disease does what it is designed to do -- clear beta-amyloid plaques from the brain -- but it does not seem to help restore lost learning and memory abilities, according to a University of California, Irvine study.

The findings suggest that treating the predominant pathology of Alzheimer's disease -- beta-amyloid plaques -- by itself may have only limited clinical benefit if started after there is significant plaque growth. However, a combination of vaccination with therapies that also target related neuron damage and cognitive decline may provide the best treatment opportunity for people with this neurodegenerative disease. Study results appear in the April 2 issue of the Journal of Neuroscience.

"We've found that reducing plaques is only part of the puzzle to treat Alzheimer disease," said study leader, UC Irvine neurobiologist Elizabeth Head. "Vaccines such as this one are a good first step for effective Alzheimer's treatment, but complimentary treatments must be developed to address the complexity of the disease."

Head and colleagues studied for a two-year period in aging canines the effect of a vaccine that is currently under clinical development for treating patients with Alzheimer's disease. The vaccine contains the beta-amyloid 1-42 protein and stimulates the immune system to produce antibodies against this same protein that is in the brain plaques. Dogs are used for such studies because beta-amyloid plaques grow naturally in their brains and they exhibit cognitive declines similar to those seen in humans.

After the aged dogs with beta-amyloid-plaque growth were immunized (which is similar to starting a treatment in patients with Alzheimer's disease), the researchers found, in comparison with non-treated aged dogs, little difference in the results of behavioral tests that measure cognitive loss. Later, brain autopsies showed that although plaques had been cleared from multiple brain regions -- including the entorhinal cortex, a region of the brain involved with learning and memory and primarily affected by Alzheimer's -- damaged neurons remained.

Head said this discovery helps explain why there was little difference in the behavioral test results between immunized and nonimmunized dogs. In addition, she added, it implies that after clearing beta-amyloid plaques from the brain, the next step is to repair these neurons. This approach will be critical for treating and reversing the effects of the Alzheimer's disease.

Currently, Head and her colleagues are developing approaches to repair these damaged neurons and hope to test them clinically.

Source: University of California - Irvine

Related stories:

New Membrane Model May Unlock Secrets of Early-Stage Alzheimer's
Researchers at the National Institute of Standards and Technology and three collaborating institutions are using a new laboratory model of the membrane surrounding neurons in the brain to study how a protein long suspected of a role in early-stage Alzheimer’s disease actually impairs a neuron’s structure and function. The team’s findings are reported in a new paper in the Biophysical Journal.
Scientists demonstrate means of reducing Alzheimer's-like plaques in fly brain
Neuroscientists at Cold Spring Harbor Laboratory (CSHL) are part of a collaboration that has succeeded in demonstrating that overexpression of an enzyme in the brain can reduce telltale deposits causally linked with Alzheimer's disease.
Study identifies toxic key to Alzheimer’s disease memory loss
Using new scientific techniques, scientists have unlocked the cascade of molecular events that lead to Alzheimer’s disease. The scientific findings published in the latest edition of Nature Medicine suggest a potential new target for the development of drug therapies to fight the irreversible and degenerative disease which affects some 29.8 million people worldwide. The total worldwide societal cost of dementia was estimated at somewhere in the region of US$315.4 billion in 2005.

Gene variation linked to earlier onset of Alzheimer's symptoms
Investigators at Washington University School of Medicine in St. Louis have identified a genetic variation associated with an earlier age of onset in Alzheimer's disease.
Researchers clear up Alzheimer's plaques in mice
Blocking a common immune system response cleared up plaques associated with Alzheimer’s Disease and enabled treated mice to recover some lost memory, Yale University researchers report Friday in the journal Nature Medicine.
Researchers explore the emerging role of infection in Alzheimer's disease
The realization that pathogens can produce slowly progressive chronic diseases has opened new lines of research into Alzheimer's disease. In a special issue of the Journal of Alzheimer's Disease published May 2008, guest editors Judith Miklossy, from the University of British Columbia, and Ralph N. Martins, from Edith Cowan University and Hollywood Private Hospital, Perth, Western Australia, and a group of experts explore this exciting topic.
Vaccine triggers immune response, prevents Alzheimer's
A vaccine created by University of Rochester Medical Center scientists prevents the development of Alzheimer’s disease-like pathology in mice without causing inflammation or significant side effects.
Study links diabetes and Alzheimer's disease
Diabetic individuals have a significantly higher risk of developing Alzheimer’s disease but the molecular connection between the two remains unexplained. Now, researchers at the Salk Institute for Biological Studies identified the probable molecular basis for the diabetes – Alzheimer’s interaction.

News discussion:

Medicine & Health news